ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: hillary kapan who wrote (242)	2/9/1998 1:13:00 AM
From: Jongmans	Read Replies (1) of 4474

Lehman's Price Target $ 11 In a report dated 02/05/98 Lehman's analysts CA Butler, PhD/EEnde, MD conclude: " * We suggest that key events for the stock in the near-term will tend to be clinical/regulatory and strategic in nature, and not necessarily financial * We anticipate several major events in the near-term including a partnership in inflammation and the gene therapy programs in 1H98 * We expect IND filings in the gene therapy program in the 1q98 as well as another signaling program in early 1998 * The current technology value of Ariad is $ 51.5 million ( with cash of $ 29.3 million). With a valuation that remains attractive over the longer-term, we reaffirm our V1-Venture rating." Full report on: lehman.com best regards Martin

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next